Navigation Links
Echo Therapeutics Announces Third Quarter 2012 Financial Results
Date:11/8/2012

PHILADELPHIA, Nov. 8, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced its financial results for the quarter ended September 30, 2012. Echo's Quarterly Report on Form 10-Q, as filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com.

(Logo:  http://photos.prnewswire.com/prnh/20120801/NE50071LOGO )

Recent Corporate Highlights

  • In preparation for its planned first quarter 2013 ISO audit, Echo made substantial advances towards finalizing its quality management systems.  ISO certification is a key step towards achieving compliance with European regulatory requirements.
  • Echo initiated the process of conducting clinical studies at investigational sites in Europe and the U.S. to support CE Mark and other commercialization efforts.
  • Echo hired key development, product, and clinical personnel to prepare for and accelerate its plans for Symphony's European and U.S. regulatory clearance and commercialization.
  • "We had a very productive third quarter, with significant progress made towards the Company's clinical, development and regulatory objectives needed to commercialize our Symphony system," commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics.  "As we look toward 2013, we remain focused on obtaining European clearance of Symphony and its commercial launch, as well as initiating our pivotal studies to support PMA submission in the U.S."

    Third Quarter 2012 Financial Results
    Echo's net loss for the third quarter of 2012 was $4.3 mil
    '/>"/>

    SOURCE Echo Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
    2. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
    3. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    4. Novelos Therapeutics Closes $2 Million Private Placement
    5. US Allows Two Key Patents for Silence Therapeutics
    6. United Therapeutics Corporation Reports Third Quarter 2012 Financial Results
    7. Cell Therapeutics, Inc. (CTI) Reduces Net Loss for Third Quarter and Nine Months Ended September 30, 2012 Compared to Same Periods in 2011
    8. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
    9. United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable Treprostinil For Pulmonary Arterial Hypertension
    10. Mersana Therapeutics Named a "Fierce 15" Biotech Company for 2012
    11. Cell Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Rule
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... Belgium and LONDON , July 31, ... (CRO) and services provider for the medical industries, announced today the ... The United Kingdom has one of ... at USD 8.9 billion in 2012 and it is projected to ... estimated at USD 234 billion in 2012, equal to 9.5% of ...
    (Date:7/31/2014)... NORTHBROOK, Ill. , July 31, 2014 /PRNewswire/ ... as the head of corporate and employee communications ... to Jeff Winton , senior vice president, ... be responsible for developing and leading corporate brand ... business goals across North and South ...
    (Date:7/31/2014)... , July 31, 2014 The Galien Foundation ... Prix Galien USA Awards. The ... accolade and recognizes the technical, scientific and clinical research ... This year brings the highest number of nominees ... USA . Nominees include biomedical products across three ...
    Breaking Medicine Technology:genae Opens Offices in London 2Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 3The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 4The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 5
    ... authorization for prescription medications is a time-consuming process for ... faxes and hard-copy request forms. While some on-line solutions ... solution and one that is integrated with available e-prescribing ... in the marketplace, CVS Caremark (NYSE: CVS ...
    ... SHENZHEN, China, May 16, 2011 /PRNewswire-Asia/ -- Global ... or the "Company"), a China-based leading vertically integrated ... and herbal cultivation businesses through its subsidiaries in ... its unaudited financial results for the first quarter ...
    Cached Medicine Technology:CVS Caremark to Pilot Electronic Prior Authorization to Help Speed Patient Access to Prescription Medication 2CVS Caremark to Pilot Electronic Prior Authorization to Help Speed Patient Access to Prescription Medication 3Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 2Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 3Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 4Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 5Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 6Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 7Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 8Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 9Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 10Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 11
    (Date:7/31/2014)... 31, 2014 Women in the Los ... of their financial future. The Independent Woman , ... registration for 6 upcoming Los Angeles area events. ... and with input from Kim Kiyosaki, a successful investor, ... Time) who is passionate about women’s financial education. , ...
    (Date:7/31/2014)... York (PRWEB) July 31, 2014 Transvaginal ... Inc. continue to move forward in the federal multidistrict ... West Virginia, Bernstein Liebhard LLP reports. According to an ... to consider certain defense motions now pending before the ... U.S. Magistrate Judge on Tuesday, August 5th at 2:30 ...
    (Date:7/31/2014)... York (PRWEB) July 31, 2014 ... as Bernstein Liebhard LLP notes that Johnson & ... plans to voluntarily remove its power morcellators ( ... report from Bloomberg.com, the company said it decided ... associated with the devices remain uncertain.* , “In ...
    (Date:7/31/2014)... CO (PRWEB) July 31, 2014 Ticket ... vs. Bolivia tickets at Dick’s Sporting Goods Park in ... years, the Mexican national soccer team has found a second ... and failures during their time playing international friendly games and ... Bolivia at Dick’s Sporting Goods Park in Commerce City, Colorado. ...
    (Date:7/31/2014)... New York, NY (PRWEB) July 31, 2014 ... ( http://www.biotechniques.com ) is now available as an ... , P-LinK: A method for generating ... surface chemistry for sensors , A ... rearrangements using high-throughput next-generation sequencing , ...
    Breaking Medicine News(10 mins):Health News:The Independent Woman to Offer Financial Workshops in the Los Angeles Area - Developed by Women for Women 2Health News:Ethicon Transvaginal Mesh Lawsuits Move Forward, With Scheduling of Hearing in Federal Litigation, Bernstein Liebhard LLP Reports 2Health News:Ethicon Transvaginal Mesh Lawsuits Move Forward, With Scheduling of Hearing in Federal Litigation, Bernstein Liebhard LLP Reports 3Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 3Health News:Mexico vs. Bolivia Tickets at Dick’s Sporting Goods Park in Commerce City (Denver), CO Now Available at Ticket Down 2Health News:Mexico vs. Bolivia Tickets at Dick’s Sporting Goods Park in Commerce City (Denver), CO Now Available at Ticket Down 3Health News:BioTechniques: The International Journal of Life Science Methods Announces the Publication of the July 2014 Issue—Available in Print and Online as an Open Access Journal 2Health News:BioTechniques: The International Journal of Life Science Methods Announces the Publication of the July 2014 Issue—Available in Print and Online as an Open Access Journal 3
    ... of DHA (docosahexaenoic acid) in the early diet of some ... of girls, according to a study published in the January ... Medical Association (JAMA) . DHA is an important nutrient for ... in mother,s milk and, in recent years, in infant formulas. ...
    ... 26 KV Pharmaceutical,(NYSE: KVa/KVb) has voluntarily suspended the manufacturing ... that it distributes but does,not manufacture. The suspension began ... the company will conduct a voluntary recall of most of ... currently under discussion,with the U.S. Food and Drug Administration (FDA). ...
    ... Inc. (OTC Bulletin Board: EFSF.OB), an emerging healthcare ... dermatology, environmental and nutraceutical products, today announced signing ... Relations and The Ruth Group (TRG). Recently, ... with Freedom2 Holdings, Inc. The merger is on ...
    ... for a Long and Vigorous LifeSAN FRANCISCO, Jan. 26 ... in a hospital bed. By some estimates, half of ... smoking as the leading cause of degenerative illness, many ... habits. However, with so much information floating around about ...
    ... way to boost protection from severe respiratory illnesses such as ... South Wales (UNSW) has found, but convincing a reluctant public ... world-first clinical trial of the efficacy of masks, researchers found ... likely than non-wearers to be protected against respiratory viruses, including ...
    ... N.Y., Jan. 26 Many moms, New Year Resolutions ... new Beech-Nut,Advancing Nutrition Survey of more than 400 American ... third (29 percent) of moms give,themselves a C or ... gets the right,amount of vitamins and minerals. Hoping baby ...
    Cached Medicine News:Health News:New Study: Higher DHA Levels Improve Neurodevelopmental Outcomes in Premature Girls 2Health News:New Study: Higher DHA Levels Improve Neurodevelopmental Outcomes in Premature Girls 3Health News:New Study: Higher DHA Levels Improve Neurodevelopmental Outcomes in Premature Girls 4Health News:KV Pharmaceutical Suspends Product Manufacturing, Shipping 2Health News:KV Pharmaceutical Suspends Product Manufacturing, Shipping 3Health News:KV Pharmaceutical Suspends Product Manufacturing, Shipping 4Health News:KV Pharmaceutical Suspends Product Manufacturing, Shipping 5Health News:eFoodSafety.com Selects Arcand & Madison as Public Relations Counsel and The Ruth Group as Investor Relations Counsel 2Health News:eFoodSafety.com Selects Arcand & Madison as Public Relations Counsel and The Ruth Group as Investor Relations Counsel 3Health News:Medical Experts Use Data to Dispel Myths About Fad Diets and Exercise 2Health News:Medical Experts Use Data to Dispel Myths About Fad Diets and Exercise 3Health News:Unmasked and vulnerable 2Health News:New Survey: Moms Need More Help on Nutrition Information 2Health News:New Survey: Moms Need More Help on Nutrition Information 3Health News:New Survey: Moms Need More Help on Nutrition Information 4
    ... Offering a unique, empowering alternative to ... industry for years, MMD's PalmScan AP2000 is ... and Pachymeter combination unit on the market ... ounces and is able to perform multiple ...
    ... is an accurate, reliable, portable, and ... It works off of a dual-rechargeable ... the device a breeze. The large, ... operating and viewing results simple. Built ...
    The Cordis ANGIOGUARD Capture Guidewire is the first embolic protection device shown in clinical testing to achieve a relative stroke reduction of 70% during carotid stenting procedures....
    ... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
    Medicine Products: